New Third Board Company Tiansong Medical again planned the listing of the Beijing Stock Exchange. The company once "broke through the level" IPO last year was not approved.Sorart, who has withdrawn the application for listing of the Bei Stock Exchange, is now being listed on the North Stock Exchange.
The listing heat of the Beijing Stock Exchange continues to decrease. After a number of new third board companies change the counseling agency, they will enter the Bei Stock Exchange again.Some companies from the Shanghai Stock Exchange from the Shanghai and Shenzhen IPO.
Secondly entering the North Stock Exchange to go public
Some New Third Board Company, which has failed to fail on the North Stock Exchange, after a year later, one year laterChoose to go to the North Stock Exchange again.
Tiansong Medical launched the listing counseling of the Bei Stock Exchange again.February 19, 2024.
This time Tiansong Medical is the second to enter the Beibei Stock Exchange.The company had previously made two breakthroughs in the IPO of the Stock Exchange. The results of the first meeting in December 19, 2022 were reviewed as "suspended review", and then it was not approved on January 30, 2023.
In the first meeting, Tiansong Medical was required to take a valid wayTruth; R & D costs and sales costs are significantly lower than the rationality of comparable companies in the same industry; whether dealers and customers have a substantial relationship with the issuer, whether the dealers are controlled by the issuer, whether the dealer is the issuer on behalf of the issuer,Cost costs; income during the reporting period has not increased, but the inventory of more than three years accounts for relatively high inventory.
When the second meeting is attended, the fundraising project has attracted attention again.project.
On February 2, 2023, the company received a decision to terminate the listing review issued by the Beijing Stock Exchange.The listed committees review believes that the issuer and intermediary agencies have failed to conduct a full inspection and reasonable doubts about the business and business rationality of the dealer in the previously suspended review opinions.Insufficient verification and argumentation of expenses, it failed to fully illustrate the issuers research and development capabilities and technological innovation. The relevant content matching of the disclosure of the prospectus.Article 19 and "Beijing Stock Exchange Publicly Publishing Stock Registration Management Measures for Publicly Publishing Stock Registration (Trial)", "Beijing Stock Exchange Publicly issued shares to unspecified investors to unspecified investors and listed on the" Beijing Stock ExchangeRules (Trial) Article 20 and other related regulations.After the company received the above -mentioned termination review decision, he said that he would not apply for review.
Data show that Tiansong Medical is mainly engaged in the research and development, production, sales and services of endoscopic minimally invasive medical devices.The companys main products are endoscopic and endoscopic minimally invasive medical devices. The products are mainly used for the diagnosis and treatment of diseases related to terminal medical institutions.
Earlier, the company plans to invest in the production capacity upgrade and reconstruction project, R & D center construction project, and marketing center construction project through the IPO of the Beijing Stock Exchange. It plans to use the raised funds for a total of 161 million yuan.
In terms of performance, the company reached the relevant profit requirements of the Beijing Stock Exchange: the companys net profit attributable to shareholders of the listed company in 2021 and 2022Those who are low before and after are calculated) 35.64 million yuan and 36.02 million yuan, respectively, and the average net asset yields are 19.85%and 19.15%, respectively.
The popularity of the Northern Stock Exchange continues to decrease
The enthusiasm for the listing of the New Third Board to the North Stock Exchange continues, some companies planChange the counseling agency, and then continue to march to the Bei Stock Exchange.
Sorat plans to change the counseling agency to continue sprinting the Beijing Stock Exchange. According to the company, due to the companys strategic development needs, the company terminated the previous counseling.Signed a counseling agreement with the new counseling agency, and reported to the Jiangsu Securities Regulatory Bureau to the Beijing Stock Exchange Listing Counseling filing materials on February 18, 2024.
Previously, Soncet joined the Beijing Stock Exchanges acceptance team on June 17, 2022 and experienced two rounds of inquiries, but November 9, 2022The company announced the withdrawal of the Bei Stock Exchanges listing application plan, and officially terminated the listing review on November 22, 2022.
After more than a year of counseling, Oufu Electric has also been changed recently. The company signed a counseling agreement with the new counseling agency on February 21, 2024 and inOn February 22, the local Securities Regulatory Bureau submitted the application materials for counseling filing.
From the perspective10,000 yuan and 48.01 million yuan, weighted average net assets yields were 16.01%and 13.25%, respectively. In the past two years, net profit was not less than 15 million yuan, and the average net asset yield of weighted net assets was not less than 8%.
It is worth mentioning that the New Third Board Company has shifted from the Shanghai -Shenzhen IPO to the listing of the Bei Stock Exchange frequently. Before the listing of the North Stock Exchange in the above -mentioned Customs Stock Exchange, Tiansong Medical and Solat have had the IPO plan of the Shanghai and Shenzhen Exchange, and Venton, which launched the Bei Stock Exchanges listing in the second degree.CSI listing plan.
Wendong latest announced that on February 22, 2024, the Qingdao Securities Regulatory Bureau accepted the first public issuance shares submitted by the company and applying for a counseling filing application for the COSCO.Coaching stage.In fact, the company has already opened a listing plan for the Beijing Stock Exchange.
Not long ago, the company announced on December 18, 2023 that it was terminated with listing counseling because the company changed the counseling agency.The company officially entered the IPO listing counseling stage on September 7, 2021. On November 3, 2022, the company submitted to the Qingdao Securities Regulatory Bureau to apply for changes in the application section.Essence
One year after receiving the listing counseling of the Beibei Stock Exchange, the company signed a termination of counseling agreement with brokers on December 12, 2023.After the Spring Festival, Wendong quickly restarted the listing plan of the Beijing Stock Exchange and signed a counseling agreement with the new counseling agency on February 21, 2024.
Market participants believe that the popularity of the NEEQ company has continued to be high, and the attractiveness of the Beijing Stock Exchange to high -quality enterprises will continue to increase. In the future, more companies will choose the Bei Stock Exchange ""Tao", but "queuing" may also occur.
Responsible editor: Zhong Tian
School pair: Zhu Tingting
The most valuable original new three-board WeChat
